Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data

被引:248
|
作者
Willan, AR
Briggs, AH
Hoch, JS
机构
[1] Hosp Sick Children, Program Populat Hlth Sci, Toronto, ON M5G 1X8, Canada
[2] Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada
[3] Univ Oxford, Hlth Econ Res Ctr, Oxford OX1 2JD, England
[4] Univ Western Ontario, Dept Epidemiol & Biostat, London, ON N6A 3K7, Canada
关键词
cost-effectiveness analysis; regression; clinical trials; covariate adjustment;
D O I
10.1002/hec.843
中图分类号
F [经济];
学科分类号
02 ;
摘要
The current interest in undertaking cost-effectiveness analyses alongside clinical trials has lead to the increasing availability of patient-level data on both the costs and effectiveness of intervention. In a recent paper, we show how cost-effectiveness analysis can be undertaken in a regression framework. In the current paper we develop a direct regression approach to cost-effectiveness analysis by proposing the use of a system of seemingly unrelated regression equations to provide a more general method for prognostic factor adjustment with emphasis on sub-group analysis. This more general method can be used in either an incremental cost-effectiveness or an incremental net-benefit approach, and does not require that the set of independent variables for costs and effectiveness be the same. Furthermore, the method can exhibit efficiency gains over unrelated ordinary least squares regression. Copyright (C) 2003 John Wiley Sons, Ltd.
引用
收藏
页码:461 / 475
页数:15
相关论文
共 50 条
  • [21] Covariate Adjustment for Logistic Regression Analysis of Binary Clinical Trial Data
    Jiang, Honghua
    Kulkarni, Pandurang M.
    Mallinckrodt, Craig H.
    Shurzinske, Linda
    Molenberghs, Geert
    Lipkovich, Ilya
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2017, 9 (01): : 126 - 134
  • [22] COVARIATE IMBALANCE AND ADJUSTMENT FOR LOGISTIC REGRESSION ANALYSIS OF CLINICAL TRIAL DATA
    Ciolino, Jody D.
    Martin, Renee H.
    Zhao, Wenle
    Jauch, Edward C.
    Hill, Michael D.
    Palesch, Yuko Y.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2013, 23 (06) : 1383 - 1402
  • [23] Cost-effectiveness analysis: Methods and applications
    Plank, DN
    COMPARATIVE EDUCATION REVIEW, 2002, 46 (01) : 141 - 143
  • [24] Median-based incremental cost-effectiveness ratios with censored data
    Bang, Heejung
    Zhao, Hongwei
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2016, 26 (03) : 552 - 564
  • [25] Bayesian sample size determination for cost-effectiveness studies with censored data
    Beavers, Daniel P.
    Stamey, James D.
    PLOS ONE, 2018, 13 (01):
  • [26] A Tutorial on Net Benefit Regression for Real-World Cost-Effectiveness Analysis Using Censored Data from Randomized or Observational Studies
    Chen, Shuai
    Bang, Heejung
    Hoch, Jeffrey S.
    MEDICAL DECISION MAKING, 2024, 44 (03) : 239 - 251
  • [27] Cost-Effectiveness Analysis of Pharmacotherapy of Adjustment Disorder in Youth
    Dimitrijevic, Radmila Ristic
    Dimitrijevic, Snezana
    Lazic, Dijana
    Nenadovic, Milutin
    JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2013, 16 : S29 - S29
  • [28] A new tool for survival analysis: evolutionary programming/evolutionary strategies (EP/ES) support vector regression hybrid using both censored/non-censored (event) data
    Land, Walker H., Jr.
    Qiao, Xingye
    Margolis, Dan
    Gottlieb, Ron
    COMPLEX ADAPTIVE SYSTEMS, 2011, 6
  • [29] Confounding and missing data in cost-effectiveness analysis: Comparing different methods
    Härkänen T.
    Maljanen T.
    Lindfors O.
    Virtala E.
    Knekt P.
    Health Economics Review, 3 (1) : 1 - 11
  • [30] Factors Limiting Subgroup Analysis in Cost-Effectiveness Analysis and a Call for Transparency
    Gemma E. Shields
    Mark Wilberforce
    Paul Clarkson
    Tracey Farragher
    Arpana Verma
    Linda M. Davies
    PharmacoEconomics, 2022, 40 : 149 - 156